VIDEO: Low-dose naltrexone shows promise in two patients with ‘complex’ refractory Crohn’s
15 February 2022
Though further study is warranted, Leonard B. Weinstock, MD, FACP, gastroenterology specialist at the Washington University School of Medicine, reported promising results of low-dose naltrexone use among two patients with Crohn’s disease.
“This is a medication that is inexpensive, that has low risks and side effects, and generally, is something that you can add on with little regard to worrying about immunosuppression,” Weinstock said. “We have a study in the works for pediatric Crohn’s disease using LDN and we are looking for sites for patients to be enrolled.”